CN110709106A - 放射性标记的生物分子及其应用 - Google Patents

放射性标记的生物分子及其应用 Download PDF

Info

Publication number
CN110709106A
CN110709106A CN201880036082.1A CN201880036082A CN110709106A CN 110709106 A CN110709106 A CN 110709106A CN 201880036082 A CN201880036082 A CN 201880036082A CN 110709106 A CN110709106 A CN 110709106A
Authority
CN
China
Prior art keywords
compound
vhh
biomolecule
radiolabeled
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880036082.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·扎鲁斯基
G·瓦德雅纳坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN110709106A publication Critical patent/CN110709106A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880036082.1A 2017-03-30 2018-03-29 放射性标记的生物分子及其应用 Pending CN110709106A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762478754P 2017-03-30 2017-03-30
US62/478,754 2017-03-30
US201762500692P 2017-05-03 2017-05-03
US62/500,692 2017-05-03
US201762529532P 2017-07-07 2017-07-07
US62/529,532 2017-07-07
US201762583134P 2017-11-08 2017-11-08
US62/583,134 2017-11-08
PCT/IB2018/052211 WO2018178936A1 (en) 2017-03-30 2018-03-29 Radiolabeled biomolecules and their use

Publications (1)

Publication Number Publication Date
CN110709106A true CN110709106A (zh) 2020-01-17

Family

ID=62017598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880036082.1A Pending CN110709106A (zh) 2017-03-30 2018-03-29 放射性标记的生物分子及其应用

Country Status (5)

Country Link
US (2) US20200188541A1 (cg-RX-API-DMAC7.html)
EP (1) EP3600453A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020512348A (cg-RX-API-DMAC7.html)
CN (1) CN110709106A (cg-RX-API-DMAC7.html)
WO (1) WO2018178936A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118388451A (zh) * 2024-06-28 2024-07-26 四川大学 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102899941B1 (ko) 2019-05-24 2025-12-16 듀크 유니버시티 18f-방사선 표지된 생체 분자
EP4058423A1 (en) 2019-11-13 2022-09-21 Duke University Radiohalogen prosthetic moieties and radiolabeled biomolecules
EP3967674A1 (en) * 2020-09-11 2022-03-16 Precirix N.V. Reactions of radioactive compounds facilitated by a solid phase
EP4337265A4 (en) * 2021-05-14 2026-03-25 Purdue Research Foundation TARGETED FOLATE RECEPTOR CONJUGATIONS WITH BRUSH-ON ENZYME-CLEVABLE BINDERS AND METHODS OF USE IN CANCER IMAGING AND TREATMENT
KR20240095178A (ko) * 2021-09-01 2024-06-25 듀크 유니버시티 단백질을 방사성 할로겐으로 부위-특이적 표지하기 위한 시약 및 이의 제조방법 및 사용 방법
AU2023276697A1 (en) 2022-05-23 2024-12-12 Cereius, Inc. Her2-binding agents and uses thereof
WO2026128025A2 (en) 2024-07-03 2026-06-18 Solve Therapeutics, Inc. Anti-ror2 antibody-radionuclide conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120251A2 (en) * 2005-12-22 2007-10-25 Duke University Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters
WO2014179715A1 (en) * 2013-05-02 2014-11-06 Duke University Prosthetic compounds for labeling internalizing biomolecules
US20160030606A1 (en) * 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5302700A (en) 1988-05-23 1994-04-12 Duke University Radiohalogenation conjugate technology
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
KR101389166B1 (ko) 2011-01-12 2014-04-24 미쯔비시 레이온 가부시끼가이샤 활성 에너지선 경화성 수지 조성물, 미세 요철 구조체 및 미세 요철 구조체의 제조 방법
KR101279584B1 (ko) 2011-06-24 2013-06-28 대한민국 (식품의약품안전처장) Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120251A2 (en) * 2005-12-22 2007-10-25 Duke University Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters
US20090304585A1 (en) * 2005-12-22 2009-12-10 Duke University Stabilized Compositions and Methods for Radiolabeling Pharmaceuticals with Alpha-Particle Emitters
WO2014179715A1 (en) * 2013-05-02 2014-11-06 Duke University Prosthetic compounds for labeling internalizing biomolecules
US20160074541A1 (en) * 2013-05-02 2016-03-17 Duke University Prosthetic Compounds for Labeling Internalizing Biomolecules
US20160030606A1 (en) * 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. VAIDYANATHAN等: "SIB-DOTA: A trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
HIROMICHI AKIZAWA等: "Renal Brush Border Enzyme-Cleavable Linkages for Low Renal Radioactivity Levels of Radiolabeled Antibody Fragments", 《BIOCONJUGATE CHEM.》 *
JAEYEON CHOI等: "N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization", 《NUCLEAR MEDICINE AND BIOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118388451A (zh) * 2024-06-28 2024-07-26 四川大学 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
US20200188541A1 (en) 2020-06-18
WO2018178936A1 (en) 2018-10-04
JP2020512348A (ja) 2020-04-23
US20250073359A1 (en) 2025-03-06
EP3600453A1 (en) 2020-02-05
JP2023076712A (ja) 2023-06-01
JP2025071280A (ja) 2025-05-02

Similar Documents

Publication Publication Date Title
US20250073359A1 (en) Radiolabeled biomolecules and their use
ES2981335T3 (es) Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
KR102397783B1 (ko) Pd-l1 결합 폴리펩티드에 의한 pet 영상화
Perols et al. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules
US9839704B2 (en) Prosthetic compounds for labeling internalizing biomolecules
AU2011354599A1 (en) Radiolabled HER2 binding peptides
CN103402550B (zh) 用含有18f的有机硅化合物标记的her2结合肽
JP2015057415A (ja) 放射免疫コンジュゲートおよびその使用
US20230340111A1 (en) Antibody fragment against folr1
US20230381350A1 (en) Antibody fragment against fap
JP2024511281A (ja) 抗cldn18.2抗体コンジュゲート
Nakashima et al. Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates
JP2025522306A (ja) Her2-結合剤およびその使用
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
WO2026083399A1 (en) Conjugates and use of same for theranostics
TW202400240A (zh) 抗vegf抗體的放射性複合體及放射性醫藥
CA3285616A1 (en) Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
CN116077686A (zh) 可酶切Linker及其用途
CN119584994A (zh) 预靶向
JP2024534909A (ja) 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法
HK1191244A (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound
HK1192847A (en) Radiolabled her2 binding peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination